Using AI to analyze abdominal aortic aneurysms
REGISTRY on the Implementation of Artificial Intelligence in the Automatic Analysis of Vascular Network Segmentation
This study is testing whether using artificial intelligence to analyze CT scans can help doctors better measure and predict problems with abdominal aortic aneurysms in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT06451315 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of artificial intelligence in the automatic analysis of vascular network segmentation for patients with abdominal aortic aneurysms (AAA). The researchers hypothesize that AI can improve the accuracy and efficiency of measuring AAA size and predicting complications compared to traditional methods. By utilizing advanced segmentation software, the study seeks to provide a more reliable volumetric assessment of AAAs, which may enhance clinical decision-making regarding treatment and follow-up. Participants will undergo pre-operative CT scans analyzed by both AI and hospital practitioners to compare outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with an AAA treated with endovascular aortic repair that meets specific size criteria.
Not a fit: Patients with advanced Alzheimer's disease, those who oppose data usage for research, or those with a life expectancy of less than two years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate assessments of AAA, potentially reducing the risk of complications and improving patient outcomes.
How similar studies have performed: While volumetric assessment has shown promise in research, this study represents a novel application of AI in clinical practice for AAA management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female ≥18 years of age * AAA treated with EVAR between * ≥50mm * or ≥5mm increase in 6 months * The subject is legally competent, has been informed of the nature, the scope, and the relevance of the study and has not manifested an opposition to participate. * Available for set-up and proper implementation of follow-up visits (standard of care) throughout the duration of the registry Exclusion Criteria: * Advancing Alzheimer's disease or socially dependent patient * Opposition to the use of their data for this research * Life expectancy supposed to be inferior to 2 years * Pregnant woman
Where this trial is running
Bordeaux
- Service de Chirurgie Vasculaire, Hôpital Pellegrin-tripode, CHU de Bordeaux — Bordeaux, France (Recruiting)
Study contacts
- Principal investigator: Eric DUCASSE, MD, PhD — University Hospital, Bordeaux
- Study coordinator: Eric DUCASSE, MD, PhD
- Email: eric.ducasse@chu-bordeaux.fr
- Phone: +33 5 56 79 55 25
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.